AzTrials
AzTrials

Type 2 Diabetes MellitusBALANCENCT07472855

Feasibility and Preliminary Efficacy of a Theory-driven BALANCE Dietary Program Among Patients With Type 2 Diabetes

A study testing Psychological capability education, Physical capability education and motivation management in people with Type 2 Diabetes Mellitus, run by Capital Medical University at 1 site in China.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This study explores the effect of an individualized dietary intervention program based on COM-B theory on improving health outcomes in patients with T2DM, improvement in metabolic health indicators and an increased diabetes remission rate, as well as changes in dietary adherence, self-management ability, and… Read more about this study

Who is it for?
Any age
Conditions the study is for
Type 2 Diabetes Mellitus
What is being tested?
Psychological capability education, Physical capability education and motivation management
Could I receive a placebo?
No, everyone receives an active treatment
How many people
30 participants
Where
1 siteChina
Study dates
1 Jun 2025to 1 Dec 2025
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Any age
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Who may be able to join

  • Meet 1999 WHO diagnostic criteria for type 2 diabetes mellitus (diabetes symptoms plus random plasma glucose ≥11.1 mmol/L, or fasting plasma glucose ≥7.0 mmol/L, or 2-hour plasma glucose ≥11.1 mmol/L after OGTT) Glycated hemoglobin (HbA1c) between 7% and 10%;
  • Stable glucose-lowering medication regimen as assessed by physician;
  • Age 18-60 years;
  • Light physical labor in the past 6 months (work mainly involving standing or small amount of walking);
  • Willing to participate voluntarily, understand study content, and able to attend regular follow-up;

Who cannot join

  • Currently using weight-loss medications;
  • Significant renal insufficiency (creatinine ≥1.5 mg/dL or 133 μmol/L);
  • Significant liver dysfunction (ALT more than 2 times the upper limit of normal);
  • History of stroke or myocardial infarction;
  • Other serious diseases including malignant tumors, psychiatric disorders, anorexia, or gastrointestinal diseases;
  • Pregnancy, planning pregnancy, postpartum status, or breastfeeding;

Trial locations and contacts

1 site in 1 country.

China1 site
  • Beijing Luhe Hospital, Capital Medical University

    Beijing

Other trials in China

About this study

This study explores the effect of an individualized dietary intervention program based on COM-B theory on improving health outcomes in patients with T2DM, improvement in metabolic health indicators and an increased diabetes remission rate, as well as changes in dietary adherence, self-management ability, and self-efficacy.

Read the detailed description

This study explores the effect of an individualized dietary intervention program based on the Capability, Opportunity, Motivation-Behavior (COM-B) theory on improving health outcomes in patients with type 2 diabetes mellitus (T2DM), including glycemic control, improvement in metabolic health indicators. The control group will implement a standardized diabetes management, including health guidance, WeChat group management, and supervision and management via a metabolic management center(MMC) mini-program. On the basis of the control group, the intervention group will implement a dietary intervention model based on the COM-B theory model and a TDF framework, including ① psychological capability education: intensified education on diabetes knowledge; ② physical capability education: intensified training in practical skills; ③ motivation management: action planning, behavior goal setting, reward mechanisms, and establishing role models; ④ support and supervision: empowerment management via a WeChat group, social support, problem solving, and guidance based on indicator monitoring on the clinician side of a health diet APP. We will observe dietary-related glycemic control, improvement in metabolic health indicators, as well as changes in dietary adherence, self-management ability, and self-efficacy.

Being tested
Psychological capability education, Physical capability education, motivation management, support and supervision, A standardized diabetes care
Keywords
COM-B theory, type 2 diabetes, behaviour change technique
Medical subject headings
Diabetes Mellitus, Type 2

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Psychological capability educationBehavioural

    Intensified education on diabetes knowledge

  • Physical capability educationBehavioural

    Intensified training in practical skills for dietary management

  • motivation managementBehavioural

    action planning, behavior goal setting, problem solving, reward mechanisms, and establishing role models

  • support and supervisionBehavioural

    empowerment management via a WeChat group, social support, and guidance based on indicator monitoring on the clinician side of a mini-program

  • A standardized diabetes careBehavioural

    a routine dietary management model will be implemented, including health guidance, WeChat group management, and supervision and management

Study groups in NCT07472855
Study groupRoleWhat they receive
The BALANCE dietary interventionExperimentalThe intervention group will implement a BALANCE dietary intervention based on the COM-B theory model and a TDF framework, including ① psychological capability education: intensified education on diabetes knowledge; ② physical capability education: intensified training in practical skills for dietary management; ③ motivation management: action planning, behavior goal setting, problem solving, reward mechanisms, and establishing role models; ④ support and supervision: empowerment management via a WeChat group, social support, and guidance based on indicator monitoring on the clinician side of a mini-program.
Receives: Behavioral: Psychological capability education; Behavioral: Physical capability education; Behavioral: motivation management; Behavioral: support and supervision
usual careActive comparatorA routine dietary management will be implemented, including health guidance, WeChat group management, and supervision and management
Receives: Behavioral: A standardized diabetes care

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. HbA1c

    HbA1c will be measured using High-Performance Liquid Chromatography (HPLC), the internationally recognized reference method for HbA1c quantification. Venous blood samples will be collected in EDTA-anticoagulated tubes and analyzed by ion-exchange HPLC, which separates hemoglobin fractions based on their interaction with a chromatography column. Results will be reported as a percentage (%) per NGSP/DCCT standards, with parallel reporting in mmol/mol per IFCC standards. All analyses will be performed in a certified laboratory participating in external quality assessment (EQA) programs to ensure inter-laboratory comparability and result accuracy.

    Measured: before the intervention and from enrollment to the end of treatment at 12 and 24 weeks

Secondary outcomes (23)
  1. FBG (Fasting Blood Glucose)

    Fasting Blood Glucose (FBG) was measured after an overnight fast of at least 8 hours. Venous blood samples were collected and analyzed using a standardized enzymatic method in a certified clinical laboratory. FBG values were reported in mg/dL. Fasting was defined as no caloric intake except water during the fasting period. The measure reflects baseline glucose levels and was used to assess glycemic status according to established clinical criteria.

    Measured: before the intervention and from enrollment to the end of treatment at 12 and 24 weeks

  2. TG (Triglycerides)

    Serum total cholesterol was measured to assess overall lipid metabolism status. After an overnight fast of at least 8 hours, venous blood samples were collected and serum total cholesterol concentration was determined using an enzymatic colorimetric method (cholesterol oxidase-peroxidase, CHOD-PAP). Results are reported in mmol/L (conversion: 1 mmol/L = 38.67 mg/dL). According to the Chinese Guidelines for the Prevention and Treatment of Dyslipidemia in Adults (2016 revision), desirable TC is <5.18 mmol/L, borderline high is 5.18-6.19 mmol/L, and elevated TC is ≥6.22 mmol/L. Lower values indicate improved lipid control.

    Measured: before the intervention and from enrollment to the end of treatment at 12 and 24 weeks

  3. TC (Total Cholesterol)

    Serum total cholesterol was measured to assess overall lipid metabolism status. After an overnight fast of at least 8 hours, venous blood samples were collected and serum total cholesterol concentration was determined using an enzymatic colorimetric method (cholesterol oxidase-peroxidase, CHOD-PAP). Results are reported in mmol/L (conversion: 1 mmol/L = 38.67 mg/dL). According to the Chinese Guidelines for the Prevention and Treatment of Dyslipidemia in Adults (2016 revision), desirable TC is <5.18 mmol/L, borderline high is 5.18-6.19 mmol/L, and elevated TC is ≥6.22 mmol/L. Lower values indicate improved lipid control.

    Measured: before the intervention and from enrollment to the end of treatment at 12 and 24 weeks

  4. DKT (Diabetes Knowledge Test)

    Diabetes knowledge assessed using the Chinese version of the Diabetes Knowledge Test (DKT) scale, originally developed by Fitzgerald et al. and culturally adapted and validated by Sun et al. The scale consists of 23 questions, each worth 1 point. Total score ranges from 0 to 23, with higher scores indicating better diabetes knowledge. The scale demonstrates acceptable internal consistency (Cronbach's α = 0.76).

    Measured: before the intervention and from enrollment to the end of treatment at 12 and 24 weeks

  5. DSES (Diabetes Self-Efficacy Scale)

    Self-efficacy assessed using the Diabetes Self-Efficacy Scale (DSES) developed by Lorig et al. and validated by Sun et al. The scale consists of 8 items, each rated on a scale from 1 to 10. Total score ranges from 8 to 80, with higher scores indicating stronger self-efficacy in diabetes self-management. The scale demonstrates excellent internal consistency (Cronbach's α = 0.889).

    Measured: before the intervention and from enrollment to the end of treatment at 12 and 24 weeks

  6. SDSCA (Summary of Diabetes Self-Care Activities)

    The Summary of Diabetes Self-Care Activities (SDSCA) scale will be used to evaluate patients' diabetes self-management behaviours. Originally developed by Toobert et al., the SDSCA has been translated into Chinese and validated for the Chinese population by Sun et al. The scale assesses patients' self-care performance over the preceding 7 days across five behavioural domains: general diet, specific diet, physical activity, blood glucose self-monitoring, and foot care. It comprises 11 items, each scored on a scale of 0 to 7, where 0 indicates that the behaviour was not performed on any day and 7 indicates performance on every day of the week. Total scores are calculated as the mean of all item scores, with higher scores reflecting better self-management. The Chinese version of the SDSCA has demonstrated good internal consistency, with a Cronbach's α of 0.84.

    Measured: before the intervention and from enrollment to the end of treatment at 12 and 24 weeks

  7. Insulin Resistance Index

    Insulin resistance was evaluated using the Homeostasis Model As-sessment of Insulin Resistance (HOMA-IR). HOMA-IR was calculated using the formula: HOMA-IR = [FPG (mmol/L) × FINS (μU/mL)] / 22.5. Higher HOMA-IR values indicate greater insulin resistance.

    Measured: before the intervention and from enrollment to the end of treatment at 12 and 24 weeks

  8. Insulin Sensitivity Index

    Insulin sensitivity was evaluated using the Matsuda Insulin Sensitivity Index (ISI-Matsuda), a composite measure derived from a standard 75-g oral glucose tolerance test (OGTT). Higher ISI-Matsuda values indicate greater insulin sensitivity.

    Measured: before the intervention and from enrollment to the end of treatment at 12 and 24 weeks

  9. Insulin C-peptide test

    C-peptide levels were determined using an electrochemiluminescence immunoassay (ECLIA) method. Results are reported in ng/mL and reference range is 0.78-1.89 ng/mL

    Measured: before the intervention and from enrollment to the end of treatment at 12 and 24 weeks

  10. Oral Glucose Tolerance Test

    Glucose tolerance was assessed using a standard 75-g oral glucose tolerance test (OGTT) performed according to the World Health Organization (WHO) protocol. After an overnight fast of at least 8-10 hours, a fasting venous blood sample was collected for baseline plasma glucose measurement. Participants then ingested a solution containing 75 g anhydrous glucose dissolved in 250-300 mL water within 5 minutes. Subsequent venous blood samples were collected at 30, 60, 90, and 120 minutes post-ingestion for plasma glucose measurement using the glucose oxidase or hexokinase enzymatic method. The primary outcome parameter is the 2-hour postload plasma glucose (2h-PG, mmol/L). Glucose tolerance status was classified according to WHO/ADA criteria: normal glucose tolerance (NGT): FPG <6.1 mmol/L and 2h-PG <7.8 mmol/L; impaired fasting glucose (IFG): FPG 6.1-6.9 mmol/L and 2h-PG <7.8 mmol/L; impaired glucose tolerance (IGT): FPG <7.0 mmol/L and 2h-PG 7.8-11.0 mmol/L; diabetes mellitus (DM): FPG ≥

    Measured: before the intervention and from enrollment to the end of treatment at 12 and 24 weeks

  11. High-Density Lipoprotein Cholesterol (HDL-C)

    Serum high-density lipoprotein cholesterol was measured to assess reverse cholesterol transport capacity and cardiovascular protective status. After an overnight fast of at least 8 hours, venous blood samples were collected and serum HDL-C concentration was determined using a direct homogeneous enzymatic method (direct HDL assay). Results are reported in mmol/L (conversion: 1 mmol/L = 38.67 mg/dL). Unlike TC, TG, and LDL-C, higher HDL-C values are considered protective against cardiovascular disease. According to the Chinese Guidelines for the Prevention and Treatment of Dyslipidemia in Adults (2016 revision), desirable HDL-C is ≥1.04 mmol/L and reduced HDL-C is <1.04 mmol/L.

    Measured: before the intervention and from enrollment to the end of treatment at 12 and 24 weeks

  12. Low-Density Lipoprotein Cholesterol (LDL-C)

    Serum low-density lipoprotein cholesterol was measured as the primary indicator of atherogenic lipid burden. After an overnight fast of at least 8 hours, venous blood samples were collected and serum LDL-C concentration was determined using a direct homogeneous enzymatic method (direct LDL assay). Where the direct assay was not available, LDL-C was calculated using the Friedewald equation: LDL-C = TC - HDL-C - TG/2.2 (all values in mmol/L), applicable only when TG <4.52 mmol/L. Results are reported in mmol/L (conversion: 1 mmol/L = 38.67 mg/dL). According to the Chinese Guidelines for the Prevention and Treatment of Dyslipidemia in Adults (2016 revision), desirable LDL-C is <3.37 mmol/L, borderline high is 3.37-4.12 mmol/L, and elevated LDL-C is ≥4.14 mmol/L. Target LDL-C levels were individualized according to each participant's cardiovascular risk stratification.

    Measured: before the intervention and from enrollment to the end of treatment at 12 and 24 weeks

  13. Weight

    Body composition was measured using a multi-frequency bioelectrical impedance analyzer (InBody 770, InBody Co., Ltd., Seoul, South Ko-rea). Participants fasted for ≥2 hours, avoided strenuous exercise for 24 hours, removed shoes and metal accessories, emptied their blad-ders, and stood upright for 5 minutes before testing to stabilize fluid distribution. During measurement, participants grasped hand elec-trodes with arms abducted ~30° from the body and remained still. Measured parameters included weight (kg), height (cm), BMI (kg/m²), body fat percentage (%), visceral fat area (cm²), and total body water (L). All assessments were performed at the same time of day (±2 hours) across visits.

    Measured: before the intervention and from enrollment to the end of treatment at 12 and 24 weeks

  14. Height

    Body composition was measured using a multi-frequency bioelectrical impedance analyzer (InBody 770, InBody Co., Ltd., Seoul, South Ko-rea). Participants fasted for ≥2 hours, avoided strenuous exercise for 24 hours, removed shoes and metal accessories, emptied their blad-ders, and stood upright for 5 minutes before testing to stabilize fluid distribution. During measurement, participants grasped hand elec-trodes with arms abducted ~30° from the body and remained still. Measured parameters included weight (kg), height (cm), BMI (kg/m²), body fat percentage (%), visceral fat area (cm²), and total body water (L). All assessments were performed at the same time of day (±2 hours) across visits.

    Measured: before the intervention and from enrollment to the end of treatment at 12 and 24 weeks

  15. BMI

    Body composition was measured using a multi-frequency bioelectrical impedance analyzer (InBody 770, InBody Co., Ltd., Seoul, South Ko-rea). Participants fasted for ≥2 hours, avoided strenuous exercise for 24 hours, removed shoes and metal accessories, emptied their blad-ders, and stood upright for 5 minutes before testing to stabilize fluid distribution. During measurement, participants grasped hand elec-trodes with arms abducted ~30° from the body and remained still. Measured parameters included weight (kg), height (cm), BMI (kg/m²), body fat percentage (%), visceral fat area (cm²), and total body water (L). All assessments were performed at the same time of day (±2 hours) across visits.

    Measured: before the intervention and from enrollment to the end of treatment at 12 and 24 weeks

  16. Body fat percentage

    Body composition was measured using a multi-frequency bioelectrical impedance analyzer (InBody 770, InBody Co., Ltd., Seoul, South Ko-rea). Participants fasted for ≥2 hours, avoided strenuous exercise for 24 hours, removed shoes and metal accessories, emptied their blad-ders, and stood upright for 5 minutes before testing to stabilize fluid distribution. During measurement, participants grasped hand elec-trodes with arms abducted ~30° from the body and remained still. Measured parameters included weight (kg), height (cm), BMI (kg/m²), body fat percentage (%), visceral fat area (cm²), and total body water (L). All assessments were performed at the same time of day (±2 hours) across visits.

    Measured: before the intervention and from enrollment to the end of treatment at 12 and 24 weeks

  17. Visceral fat area

    Body composition was measured using a multi-frequency bioelectrical impedance analyzer (InBody 770, InBody Co., Ltd., Seoul, South Ko-rea). Participants fasted for ≥2 hours, avoided strenuous exercise for 24 hours, removed shoes and metal accessories, emptied their blad-ders, and stood upright for 5 minutes before testing to stabilize fluid distribution. During measurement, participants grasped hand elec-trodes with arms abducted ~30° from the body and remained still. Measured parameters included weight (kg), height (cm), BMI (kg/m²), body fat percentage (%), visceral fat area (cm²), and total body water (L). All assessments were performed at the same time of day (±2 hours) across visits.

    Measured: before the intervention and from enrollment to the end of treatment at 12 and 24 weeks

  18. Waist Circumference (WC)

    A non-elastic flexible tape at the midpoint between the lowest rib margin and the iliac crest at the end of normal expiration, with the participant standing and arms relaxed at sides. Measurements were taken twice and averaged. Results are reported in cm.

    Measured: before the intervention and from enrollment to the end of treatment at 12 and 24 weeks

  19. Hip Circumference (HC)

    A non-elastic flexible tape at the level of the greatest posterior protru-sion of the buttocks, with the participant standing with feet together. Measurements were taken twice and averaged. Results are reported in cm.

    Measured: before the intervention and from enrollment to the end of treatment at 12 and 24 weeks

  20. Waist-hip ratio (WHR)

    WHR is calculated as the waist circumference divided by the hip cir-cumference.

    Measured: before the intervention and from enrollment to the end of treatment at 12 and 24 weeks

  21. Dietary behaviour diary

    Trained investigators assisted with app installation and provided standardized usage instructions at enrollment. Participants photo-graphed and logged all meals and beverages daily, and the app au-tomatically calculated total caloric intake (kcal/day) and macronutri-ent composition (carbohydrate, protein, and fat in g/day and % of to-tal energy) based on a built-in Chinese food composition database.

    Measured: before the intervention and from enrollment to the end of treatment at 12 and 24 weeks

  22. Dietary adherence

    Dietary adherence assessed using the Dietary Behaviour Compliance Scale developed by Zhao et al. The scale comprises 5 dimensions with 23 total items: fruits and vegetables (5 items), oil and salt (4 items), carbohydrates and fat (5 items), cooking and dining habits (4 items), and overall dietary self-regulation (5 items). Each item is rated on a 5-point Likert scale where 1 = "never" and 5 = "always". Total score ranges from 23 to 115, with higher scores indicating better adherence to recommended dietary behaviours. The scale demonstrates excellent internal consistency (Cronbach's α = 0.886).

    Measured: before the intervention and from enrollment to the end of treatment at 12 and 24 weeks

  23. International Physical Activity Questionnaire-Short Form (IPAQ-SF)

    Physical activity assessed using the IPAQ-SF. Participants recall and report frequency (days/week) and duration (minutes/day) of physical activity, plus total daily sitting time on weekdays, over the previous 7 days. Metabolic equivalent (MET) values are: 3.3 METs for walking, 4.0 METs for moderate-intensity activity, and 8.0 METs for vigorous-intensity activity. Weekly physical activity for each intensity is calculated as: MET-min/week = MET value × frequency (days/week) × duration (min/day). The questionnaire demonstrates good validity; correlations between weekly activity time across IPAQ-SF dimensions and pedometer-recorded total weekly step counts ranged from 0.417 to 0.440 (p < 0.05).

    Measured: before the intervention and from enrollment to the end of treatment at 12 and 24 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted16 Mar 2026
  2. Study start1 Jun 2025
  3. Primary completion1 Dec 2025
  4. Study completion1 Dec 2025

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
For the control group, a routine dietary management model will be implemented, including health guidance, WeChat group management, and supervision and management; on the basis of the control group, the intervention group will implement a BALANCE dietary intervention based on the COM-B theory model and a TDF framework, including ① psychological capability education: intensified education on diabetes knowledge; ② physical capability education: intensified training in practical skills for dietary management; ③ motivation management: action planning, behavior goal setting, problem solving, reward mechanisms, and establishing role models; ④ support and supervision: empowerment management via a WeChat group, social support, and guidance based on indicator monitoring on the clinician side of a mini-program. At 3 and 6 months after the intervention, we will observe dietary-related glycaemic control, improvement in metabolic health indicators, and diabetes remission, as well as changes in dieta
Masking
Triple blind
Who is masked
Participant, Investigator, Outcomes assessor
Enrolment
30 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07472855
Sponsor's protocol ID
LHYY2025-YJZ010
Acronym
BALANCE
Status last verified
Mar 2026
First submitted
2 Mar 2026
Last updated
16 Mar 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Psychological capability education, Physical capability education and motivation management in people with Type 2 Diabetes Mellitus, run by Capital Medical University at 1 site in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 16 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

HbA1c (time frame: before the intervention and from enrollment to the end of treatment at 12 and 24 weeks). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Mar 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in